checkedPsychopharmacology and Psychiatry Updates2026-11-13last verified 2026-11-13

does the combination film label say to start severe liver impairment on buprenorphine alone?

verdict: misattributed
a real number attached to the wrong thing
“The FDA label for the combination film recommends starting severe hepatic impairment on buprenorphine alone.”

a host said on Psychopharmacology and Psychiatry Updates, 2026-11-13, at 01:47. hear it in context → the speaker cited: the FDA label for the combination film.

the episode: Liver Disease: Buprenorphine, Methadone, and Smoking Cessation Agents (at 01:47). we link the show's own page; we do not re-host audio.

first, the part that holds

the combination-film label does steer away from buprenorphine/naloxone in severe hepatic impairment: it says the products are "not recommended" (section 5.12) and "should be avoided" (section 8.6) in that group. the label also contains a sentence about starting treatment on buprenorphine without naloxone, so the speaker is mixing two real parts of the label.

what we found when we went and looked

we read the current FDA label for buprenorphine/naloxone sublingual film on DailyMed (revised 12/2025). for severe hepatic impairment, it says the combination is not recommended or should be avoided. it does not say to start on buprenorphine alone or name any alternative. the sentence about starting on "a buprenorphine product without naloxone" is in the moderate-impairment paragraph: there, induction on the combination is not recommended, but the combination "may be used with caution for maintenance" in patients who began on the mono-product. the claim takes the moderate-impairment sequencing advice and applies it to severe impairment, where the label says to avoid the combination.

assertion by assertion

assertionverdictwhat the record says
the combination-film label advises against buprenorphine/naloxone in severe hepatic impairmentconfirmedsection 5.12 says buprenorphine/naloxone products "are not recommended in patients with severe hepatic impairment"; section 8.6 says they "should be avoided" there. the stated reason: the fixed-dose combination cannot be titrated component by component, and liver impairment cuts naloxone clearance far more than buprenorphine clearance. that raises the risk of precipitated withdrawal and may reduce buprenorphine's effect. [1]
the combination-film label recommends starting patients with severe hepatic impairment on buprenorphine alonemisattributedfor severe impairment the label only says avoid or not recommended. it does not name an alternative or a starting plan. the only mention of beginning on "a buprenorphine product without naloxone" is in the moderate-impairment paragraph of section 5.12, where the combination "may be used with caution for maintenance" in patients who started that way. it is a real sentence about a different severity tier. [1]
in moderate hepatic impairment, the label says not to start (induct) on the combinationconfirmedsection 5.12: buprenorphine/naloxone products "are not recommended for initiation of treatment (induction) in patients with moderate hepatic impairment" because of increased risk of precipitated withdrawal. section 8.6 adds that the products may not be appropriate in moderate impairment. [1]
the size of the naloxone exposure increase behind the warningconfirmedsection 12.3, table 6, from a single-dose study of the 2.0/0.5 mg combination sublingual tablet (the label gives no subject count). in severe impairment, naloxone Cmax rose 1030% and AUC 1302%, against 72% and 181% for buprenorphine. in moderate impairment, naloxone AUC rose 218% against 64% for buprenorphine. mild impairment showed no clinically significant change. [1]
buprenorphine-only labels address use in severe hepatic impairmentconfirmedbuprenorphine sublingual tablet labels say that for severe hepatic impairment, prescribers should "consider reducing the starting and titration incremental dose by half" and monitor for toxicity or overdose. so the mono-product labeling expects use in this group with adjustment. that guidance is on the mono-product label, not the combination-film label the speaker named. [2][3]

both directions

for the speaker: the combination-film label does tell prescribers not to use buprenorphine/naloxone in severe hepatic impairment, and the pharmacokinetic table makes the reason concrete: naloxone AUC rises about 13-fold over baseline (+1302%) in severe impairment, against about 2.8-fold (+181%) for buprenorphine. the label also uses "initiated treatment on a buprenorphine product without naloxone" language. buprenorphine-only labels give a severe-impairment dosing instruction (consider halving the starting and titration increments). so in practice, buprenorphine alone is the product whose labeling covers this group, and the speaker's practical point is close to how the two labels fit together.

against: the label the speaker named does not recommend buprenorphine alone for severe impairment. it does not recommend any product there. it only says to avoid the combination. the "start without naloxone" wording sits in the moderate-impairment paragraph and describes a sequence: start on the mono-product, then possibly move to the combination for maintenance with caution. in severe impairment the label offers no such path back to the combination, so presenting it as a severe-impairment starting recommendation changes both the severity tier and what the label tells prescribers to do.

what this cannot say

we read one combination-film label (the reference product, revised 12/2025) and two repackager buprenorphine-only tablet labels (2016 and 2024). generic film labels share this section, but wording can differ slightly between labelers. labels describe regulatory guidance, not clinical outcomes. the hepatic data come from one single-dose pharmacokinetic study of the combination tablet whose subject count the label does not give, and we did not read the underlying study. we cannot hear the surrounding minutes of the episode, so the speaker may have given context elsewhere that we did not assess. clinical guidelines outside the FDA label were not part of this check.

the medication pages behind this check

sources, each one fetched and read

  1. U.S. FDA prescribing information, buprenorphine and naloxone sublingual film (reference listed drug), DailyMed, revised 12/2025 What we read there: 5.12: "Buprenorphine/naloxone products are not recommended in patients with severe hepatic impairment"; not recommended for induction in moderate impairment; may be used with caution for maintenance in moderate impairment in patients "who have initiated treatment on a buprenorphine product without naloxone." 8.6: "should be avoided in patients with severe hepatic impairment." 12.3 table 6: in severe impairment, naloxone AUC +1302%, Cmax +1030%; buprenorphine AUC +181%, Cmax +72%. Fetched 2026-11-13 (HTTP 200). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8a5edcf9-828c-4f97-b671-268ab13a8ecd
  2. U.S. FDA prescribing information, buprenorphine sublingual tablet (repackager label), DailyMed, updated September 13, 2024 What we read there: 2.7, patients with severe hepatic impairment: "Consider reducing the starting and titration incremental dose by half" and monitor for toxicity or overdose. 5.12: "For patients with severe hepatic impairment, a dose adjustment is recommended." Fetched 2026-11-13 (HTTP 200). https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=2204e135-6a0c-68a2-e063-6394a90ac019
  3. U.S. FDA prescribing information, buprenorphine hydrochloride sublingual tablet (repackager label), DailyMed, revised 5/2016 What we read there: 2.5: for severe impairment, "Consider reducing the starting and titration incremental dose by half compared to patients with normal liver function"; for moderate impairment, no dose adjustment is necessary but use with caution. Fetched 2026-11-13 (HTTP 200). https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=89883285-c6f2-487a-b4bb-86f0fbded056

speakers are described by role, not named. one sentence is quoted under fair use, with attribution and a link to the original at the timestamp; we do not re-host audio or video. nothing on this page is a reason to start, stop or change a medication. if you have the file behind anything marked unverifiable, the research board is where people can answer. adam